Qiagen N.V. (ETR:QIA)

Germany flag Germany · Delayed Price · Currency is EUR
37.02
-0.59 (-1.57%)
Apr 25, 2025, 5:35 PM CET
-7.52%
Market Cap 8.20B
Revenue (ttm) 1.91B
Net Income (ttm) 80.74M
Shares Out n/a
EPS (ttm) 0.37
PE Ratio 101.51
Forward PE n/a
Dividend 1.21 (3.26%)
Ex-Dividend Date Jan 29, 2025
Volume 533,952
Average Volume 676,181
Open 37.87
Previous Close 37.61
Day's Range 37.02 - 37.90
52-Week Range 34.24 - 47.36
Beta 0.62
RSI 55.78
Earnings Date Apr 28, 2025

About Qiagen

Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights in the Netherlands and internationally. The company offers primary sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, such as kits and components for purification of nucleic acids; and... [Read more]

Sector Healthcare
Founded 1984
Employees 5,396
Stock Exchange Deutsche Börse Xetra
Ticker Symbol QIA
Full Company Profile

Financial Performance

In 2024, Qiagen's revenue was $1.98 billion, an increase of 0.66% compared to the previous year's $1.97 billion. Earnings were $83.59 million, a decrease of -75.51%.

Financial numbers in USD Financial Statements

News

QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a series of product and partnership updates designed to strengthen its portfolio for cancer genomic profiling. These new develop...

2 days ago - Wallstreet:Online

QIAGEN Advances Cancer Genomic Profiling With New Products and Partnership Updates at AACR Annual Meeting 2025

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced a series of product and partnership updates designed to strengthen its po...

2 days ago - Business Wire

Qiagen NV (QGEN) Announces Launch of New Sample Preparation Instruments | QGEN stock news

Qiagen NV (QGEN) Announces Launch of New Sample Preparation Instruments | QGEN stock news

10 days ago - GuruFocus

QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that plans are advancing to launch three new sample preparation instruments during 2025 and 2026 to expand and strengthen its portfol...

10 days ago - Wallstreet:Online

QIAGEN Advancing Plans to Launch Three New Sample Preparation Instruments by 2026 to Improve Lab Automation

VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that plans are advancing to launch three new sample preparation instruments du...

10 days ago - Business Wire

QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast

QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, May 7, shortly after 22:05 Frankfurt time ...

17 days ago - Wallstreet:Online

QIAGEN N.V. to Release Results for Q1 2025 and Hold Webcast

VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN) (Frankfurt Stock Exchange: QIA) announced plans to release results for the first quarter 2025. Press release date / time: Wednesday, M...

17 days ago - Business Wire

Qiagen gains after guidance raise

18 days ago - Seeking Alpha

Qiagen Shares Rise Premarket As Preliminary Q1 Results, Hikes FY25 EPS Guidance

Qiagen N.V. (NYSE: QGEN) shares are trading higher premarket on Monday. On Sunday, the company disclosed its preliminary results for the first quarter of 2025 . The company sees net sales growth of a...

18 days ago - Benzinga

Qiagen NV Announces Strong Q1 2025 Results and Updates Full-Year Earnings Outlook

Qiagen NV Announces Strong Q1 2025 Results and Updates Full-Year Earnings Outlook

18 days ago - GuruFocus

Qiagen NV (QGEN) Exceeds Q1 2025 Financial Expectations

Qiagen NV (QGEN) Exceeds Q1 2025 Financial Expectations

18 days ago - GuruFocus

QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary Q1 2025 results that exceeded its outlook for both net sales and adjusted earnings per share (EPS), reflecting stron...

18 days ago - Wallstreet:Online

QIAGEN Delivers Strong Preliminary Q1 2025 Results Exceeding Outlook and Raises Full-Year 2025 Adjusted EPS Outlook

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced preliminary Q1 2025 results that exceeded its outlook for both net sales and adjusted earni...

18 days ago - Business Wire

EQS-Adhoc: QIAGEN N.V.: QIAGEN announces strong preliminary Q1 2025 results and updates full-year 2025 adjusted earnings per share outlook

EQS-Ad-hoc: QIAGEN N.V. / Key word(s): Preliminary Results QIAGEN N.V.: QIAGEN announces strong preliminary Q1 2025 results and updates full-year 2025 adjusted earnings per share outlook 06-Apr-2025 /...

18 days ago - Wallstreet:Online

Qiagen NV Launches Innovative QIAprep&amp Plasmodium Kit for Malaria Research

Qiagen NV Launches Innovative QIAprep&amp Plasmodium Kit for Malaria Research

24 days ago - GuruFocus

QIAGEN Launches QIAprep&amp Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAprep&amp Plasmodium Kit and two companion assays to support malaria research and surveillance efforts. This...

24 days ago - Wallstreet:Online

QIAGEN Launches QIAprep&amp Plasmodium Kit to Strengthen Malaria Research and Surveillance Efforts

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the launch of the QIAprep&amp Plasmodium Kit and two companion assays to support malaria re...

24 days ago - Business Wire

QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statements on Form 20-F, for the year ended De...

25 days ago - Wallstreet:Online

QIAGEN Announces Form 20-F Annual Report Filing for 2024 Results

VENLO, Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) announced today that it has filed its annual report, including its audited consolidated financial statement...

25 days ago - Business Wire

Qiagen NV (QGEN) Secures FDA Clearance for New Gastrointestinal Panel

Qiagen NV (QGEN) Secures FDA Clearance for New Gastrointestinal Panel

7 weeks ago - GuruFocus

QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio

QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared the QIAstat-Dx Gastrointestinal Panel 2 Mini B for clinical use, further...

7 weeks ago - Wallstreet:Online

QIAGEN receives U.S. clearance for second QIAstat-Dx mini gastrointestinal panel, expanding U.S. syndromic testing portfolio

GERMANTOWN, Md. & VENLO, Netherlands--(BUSINESS WIRE)---- $QGEN #QIAGEN--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that the U.S. Food and Drug Administration (FDA) has cleared...

7 weeks ago - Business Wire

QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing

QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent infringement, reinforcing its commitment to protecti...

7 weeks ago - Wallstreet:Online

QIAGEN takes legal action to defend QuantiFERON intellectual property and protect innovations in latent tuberculosis testing

VENLO, The Netherlands--(BUSINESS WIRE)--QIAGEN N.V. (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced that it has filed a complaint against bioMérieux S.A. (EPA: BIM) for patent infringemen...

7 weeks ago - Business Wire